-+ 0.00%
-+ 0.00%
-+ 0.00%

Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

Reuters·11/02/2026 21:59:04

Please log in to view news